Vertex Pharmaceuticals
VRTX
522 hedge funds and large institutions have $25.8B invested in Vertex Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 186 increasing their positions, 185 reducing their positions, and 38 closing their positions.
126% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 38
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
48% more capital invested
Capital invested by funds: $17.4B → $25.8B (+$8.39B)
8% more funds holding
Funds holding: 483 → 522 (+39)
1% more repeat investments, than reductions
Existing positions increased: 186 | Existing positions reduced: 185
0.29% less ownership
Funds ownership: 95.29% → 95% (-0.29%)
1% less call options, than puts
Call options by funds: $257M | Put options by funds: $259M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.63B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$251M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$98.5M |
| 4 |
HM
HealthCor Management
New York
|
+$90.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$87.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$252M |
| 2 |
JP Morgan Chase
New York
|
-$109M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$108M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$76.6M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$72.7M |
VRTX Hedge Fund Activity: Q1 2017 in Review
522 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2017, worth a combined $25.8B — up 48% from $17.4B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new VRTX positions and 38 closed out — a net gain of 48 holders — while 186 added to existing stakes and 185 trimmed.
The largest buyer was BlackRock, adding an estimated $1.63B. The largest seller was Capital World Investors, cutting an estimated $252M.
- 522 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2017, up from 483 in Q4 2016.
- Funds reported $25.8B of Vertex Pharmaceuticals stock for Q1 2017, up 48% quarter-over-quarter.
- 86 funds opened new Vertex Pharmaceuticals positions in Q1 2017 and 38 closed out, a net change of +48 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $1.63B added.
- The largest Vertex Pharmaceuticals seller in Q1 2017 was Capital World Investors, an estimated $252M sold.
Based on aggregated 13F filings for Q1 2017.